Prostate cancer affects one in six men in their lifetime, making it one of the most prevalent cancers worldwide. The frontline treatment for prostate cancer is androgen deprivation therapy (ADT), a hormone-based approach aimed at halting tumor progression by cutting off androgen signaling. Yet, despite initial efficacy, ADT frequently loses effectiveness as tumors adapt, giving rise to a more aggressive and treatment-resistant tumor subtype known as neuroendocrine prostate cancer. This transformation, driven by cellular plasticity and lineage reprogramming, has posed a significant challenge to researchers and oncologists seeking durable treatment outcomes.

The phenomenon of lineage plasticity, whereby prostate adenocarcinoma cells undergo transdifferentiation into neuroendocrine-like cells under the selective pressure of ADT, lies at the heart of NEPC progression. Until now, the underlying molecular players orchestrating this transformation were largely unknown. By elucidating the genetic landscape of this progression, the Columbia team aimed to identify novel key drivers enabling tumor adaptability and resistance.

Using a sophisticated forward genetic screen approach in mice, the investigators screened for recurrent mutations across independent prostate tumors that promote the NEPC phenotype. This high-throughput genomic survey revealed 75 candidate genes potentially implicated in driving neuroendocrine features. Among these, Sirtuin 1 emerged as the most compelling and consistent positive regulator. Sirt1 encodes an NAD+-dependent deacetylase enzyme involved in a broad array of cellular functions, including epigenetic regulation, metabolism, DNA repair, and stress responses.

Sirt1’s role in cancer has been contentious, displaying context-dependent activities that can promote or suppress tumor growth depending on the cancer type and cellular environment. However, this new study provides convincing evidence positioning Sirt1 as a potent promoter of NEPC specifically. To validate this, the researchers employed human prostate cancer cell lines characterized by varying levels of SIRT1 expression. Inducing NEPC differentiation in these cells led to increased activation of SIRT1 target genes coupled with suppression of genes usually inhibited by SIRT1, reinforcing the enzyme’s central role in neuroendocrine lineage determination.

Further experiments showed that pharmacologically activating SIRT1 in prostate cancer cells that naturally express it at low levels provoked a robust upregulation of neuroendocrine markers, effectively mirroring the aggressive tumor phenotype. Conversely, silencing Sirt1 expression profoundly curtailed tumor growth in NEPC mouse models. This finding underscores the enzyme’s potential as a therapeutic vulnerability, as its inhibition disrupts the plasticity and dedifferentiation processes essential for tumor aggressiveness.

Perhaps most promisingly, the team evaluated the effects of Selisistat, an FDA-approved SIRT1 inhibitor originally developed for treating Huntington’s disease, on NEPC tumors in vivo. Treatment with Selisistat not only suppressed tumor progression but also notably reversed the neuroendocrine phenotype, indicating that pharmacological disruption of SIRT1 activity could restore tumor sensitivity and undermine lethal cancer progression. This repurposing of Selisistat represents a practical and accelerated pathway toward clinical application.

According to Dr. Cory Abate-Shen, professor at Columbia University Vagelos College of Physicians and Surgeons and co-leader of this research, “Our findings demonstrate that SIRT1 plays a pivotal role in promoting neuroendocrine prostate cancer. This extends beyond general tumor growth regulation to encompass lineage plasticity and cellular identity reprogramming.” This breakthrough highlights SIRT1 as an attractive and clinically actionable target deserving of expedited investigation in future clinical studies.

Complementing this therapeutic insight, the study also elucidates important mechanistic pathways regulated by SIRT1 in NEPC cells. The enzyme’s enzymatic activity influences gene expression patterns that modulate chromatin accessibility and metabolic reprogramming—two fundamental processes implicated in enabling tumor cells to escape differentiation constraints and develop therapy-resistant phenotypes. This dual-level regulation may explain the difficulty encountered in controlling NEPC progression using conventional therapies.

Moreover, by integrating genetic, molecular, and pharmacological data, the research establishes a comprehensive model in which SIRT1 activation masterfully orchestrates the complex network of transcriptional programs necessary for neuroendocrine differentiation. This gene regulatory influence is tightly linked to metabolic adaptations that support tumor survival under androgen-deprived conditions.

The implications of this research are vast, as it paves the way for the development of novel combination therapies that inhibit both androgen receptor signaling and SIRT1 function. Such strategies could effectively thwart the emergence of neuroendocrine prostate cancer at its root, improving patient outcomes and survival rates. Given the current lack of effective treatments for NEPC, these findings may mark a turning point in precision oncology for prostate cancer patients worldwide.

Columbia’s innovative approach, combining forward genetic screening with translational pharmacology, exemplifies the power of integrating genetic discovery with drug repurposing to accelerate clinical impact. While further preclinical validation and clinical trials are warranted, this study positions SIRT1 inhibition as a beacon of hope for tackling the current therapeutic impasse in lethal prostate cancer variants.

As research unfolds, the scientific and clinical communities will closely monitor the progression of SIRT1-targeted therapies through development pipelines. Should these findings be replicated in human clinical contexts, the prospect of significantly extending patient survival and quality of life becomes tangible. This work not only expands our understanding of the molecular underpinnings of cancer plasticity but also sets a blueprint for addressing other malignancies governed by similar mechanisms.

In summary, this landmark study by Nunes de Almeida and colleagues, published on May 28, 2026, in the Journal of Experimental Medicine, identifies Sirtuin 1 as a fundamental genetic driver of neuroendocrine prostate cancer and highlights the therapeutic promise of SIRT1 inhibitors like Selisistat in reversing this aggressive disease phenotype. By revealing the molecular intricacies of lineage plasticity and drug resistance, it invigorates the quest for effective treatments against one of the deadliest forms of prostate cancer.

Subject of Research: Animals
Article Title: A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer
News Publication Date: 28-May-2026
Web References: http://dx.doi.org/10.1084/jem.20241484
References: Nunes de Almeida et al. 2026. Journal of Experimental Medicine
Image Credits: © 2026 Nunes de Almeida et al. Originally published in Journal of Experimental Medicine
Keywords: Prostate cancer, Neuroendocrine prostate cancer, Sirtuin 1, NEPC, Lineage plasticity, Androgen deprivation therapy resistance, SIRT1 inhibitor, Selisistat, Tumor biology, Gene regulation

Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men worldwide. Despite decades of research, many aspects of this complex disease, including its mechanisms of initiation, progression, and resistance to therapy, remain incompletely understood. Recently, revolutionary advances in single-cell RNA sequencing (scRNA-seq) technologies have transformed the landscape of prostate cancer research, enabling unprecedented exploration of the cellular heterogeneity within tumors and their microenvironmental context. These insights are catalyzing a paradigm shift in our comprehension of prostate biology from development through malignancy, and hold promise for radically improved diagnostic and therapeutic approaches.

At its core, single-cell RNA sequencing provides the ability to profile gene expression at the resolution of individual cells, overcoming the limitations inherent in traditional bulk sequencing approaches that average signals across millions of heterogeneous cells. This granular perspective uncovers the complex mosaic of distinct cell populations within the prostate, including epithelial, stromal, and immune subtypes, each with unique transcriptomic signatures and functional roles. By charting this cellular diversity, researchers can trace the evolutionary trajectories of tumor clones, identify rare subpopulations driving disease, and understand dynamic cellular responses to stimuli such as androgen deprivation therapy.

One of the most striking revelations enabled by scRNA-seq in prostate cancer is the extent of cellular lineage plasticity, a phenomenon whereby tumor cells can shift identity and phenotype in response to environmental and therapeutic pressures. This plasticity underpins resistance mechanisms to conventional androgen receptor (AR)-targeted therapies that are the mainstay treatment for advanced disease. Through single-cell profiling, distinct states of AR dependence and independence have been mapped, uncovering transitional populations that evade therapy by adopting neuroendocrine or stem-like characteristics. These findings could inform novel therapeutic strategies aimed at intercepting or reversing such lineage switches.

Equally consequential is the elucidation of the tumor microenvironment (TME), a complex consortium of support cells including fibroblasts, endothelial cells, and diverse immune infiltrates that orchestrate tumor progression and immune evasion. scRNA-seq has unveiled remarkable heterogeneity within stromal and immune compartments, revealing subtypes that either promote or restrain tumor growth. For example, distinct populations of tumor-associated macrophages and T cells have been identified with varying roles in immunomodulation, suggesting new avenues for immunotherapy by selectively targeting pro-tumorigenic microenvironment components.

Complementing scRNA-seq, emerging spatial transcriptomics technologies now enable the localization of gene expression patterns within the intact tissue architecture. This innovation adds a critical layer of spatial context to single-cell data, preserving information on how cells are organized and interact within tumor niches. In prostate cancer, spatial mapping has been pivotal in deciphering the architecture of tumor ecosystems, revealing gradients of cellular states, spatially restricted gene expression programs, and niches enriched for therapy-resistant populations. Together, these technologies synergize to provide a multidimensional view of tumor biology with vast implications for precision medicine.

A key capability of these integrated approaches is the bioinformatic inference of large-scale genomic alterations, including copy number variants (CNVs), directly from transcriptomic data. This innovation bypasses the need for separate DNA sequencing, enabling simultaneous analysis of genomic and transcriptomic heterogeneity at single-cell resolution. In prostate cancer, this integrated genomic–transcriptomic profiling illuminates the clonal evolution of tumor cells, revealing patterns of genetic instability and their transcriptomic consequences that drive aggressive behavior and therapeutic resistance. Such insights are vital for understanding the evolutionary dynamics underpinning metastasis and relapse.

Beyond deepening biological understanding, single-cell and spatial transcriptomics offer tangible clinical potential. By resolving the cellular and molecular heterogeneity that underlies varied patient outcomes, these technologies pave the way for sub-stratification of prostate cancer patients into molecularly defined subgroups. This stratification could enhance prognostication, inform therapeutic choice, and reduce overtreatment. Furthermore, identification of novel biomarkers expressed in distinct cell populations or niches can fuel the development of more sensitive and specific diagnostic assays.

Therapeutically, the knowledge gained through scRNA-seq enables the rational design of interventions tailored to tumor subtypes and their microenvironments. For instance, targeting stromal cells that support tumorigenesis or modulating immune subsets to reverse immunosuppression could augment existing treatments. In addition, therapeutics that specifically disrupt lineage plasticity mechanisms might overcome resistance to androgen deprivation therapy, addressing a major clinical challenge in advanced prostate cancer management.

Importantly, the technological and computational sophistication required to perform and interpret single-cell and spatial transcriptomic data is rapidly maturing. Advances in sequencing platforms, microfluidics, and imaging techniques, combined with innovative algorithms for data integration and visualization, are fostering wider accessibility and scalability of these powerful tools. This democratization is accelerating discoveries in prostate cancer biology and expanding possibilities across oncology and beyond.

Nevertheless, significant challenges remain. Integrating multimodal datasets, including transcriptomic, proteomic, epigenetic, and genomic information, at single-cell resolution remains computationally intensive and technically demanding. Moreover, standardization of protocols and analytical pipelines is necessary to ensure reproducibility and comparability across studies. Addressing tumor heterogeneity in diverse patient populations and disease contexts also requires extensive sampling and longitudinal analyses.

Looking ahead, the convergence of single-cell and spatial transcriptomics with other emerging modalities such as single-cell ATAC-seq, proteogenomics, and high-throughput imaging promises to fully characterize the prostate tumor ecosystem across multiple dimensions. Coupling these data with clinical parameters and treatment responses through integrative artificial intelligence approaches could unlock predictive models for personalized therapy. Ultimately, these advances will transform prostate cancer from an enigmatic and heterogeneous disease into one that can be precisely dissected, monitored, and conquered.

The journey from organogenesis to metastatic prostate cancer is being rewritten through the lens of single-cell biology. As researchers continue to unravel the intricate interplay of epithelial, stromal, and immune networks within the prostate, new vulnerabilities emerge to challenge the resilience of cancer. These insights herald a new age of precision oncology where therapy is tailored not only to the genetic makeup of the tumor but also to its cellular architecture, evolutionary trajectory, and microenvironmental crosstalk. The promise of single-cell and spatial RNA sequencing for prostate cancer is immense—offering hope for improved outcomes and survival for millions of men worldwide.

Subject of Research: Prostate cancer biology and tumor microenvironment characterization through single-cell and spatial transcriptomics.

Article Title: Single-cell and spatial RNA sequencing in prostate cancer

Article References:
Ali, A., Mikutenaite, M., Weischenfeldt, J. et al. Single-cell and spatial RNA sequencing in prostate cancer. Nat Rev Urol (2026). https://doi.org/10.1038/s41585-026-01149-4

Image Credits: AI Generated